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Abstract: Natalizumab was the first monoclonal antibody to be approved for the treatment 
of relapsing-remitting multiple sclerosis (RRMS) based on its short-term efficacy and overall 
tolerability. However, the incidence of treatment-associated progressive multifocal leukoenceph-
alopathy (PML), an infection of the brain caused by the John Cunningham virus, jeopardized 
this efficacious treatment from the beginning. Eight years after licensing of natalizumab, long-
term studies confirm the considerable and sustained efficacy of natalizumab, although the PML 
complication still threatens one of the most successful treatments available for RRMS. During 
these years, considerable progress has been made in identification of risk factors that allow 
more effective management of PML risk. In addition, long-term studies to define better when 
to start or stop treatment and to optimize treatment strategies after cessation of natalizumab are 
ongoing, and hopefully will improve management and will allow natalizumab to remain as a 
valuable therapeutic option for patients with highly active RRMS.
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Introduction
Multiple sclerosis (MS) is a chronic inflammatory, demyelinating, and neurode-
generative disease that affects the central nervous system (CNS).1 Affecting over 
2 million people worldwide, MS usually starts at 20–40 years of age and is the 
most common cause of neurological disability in young adults. Although not all 
genetic and environmental risk factors are known, the etiology of MS involves 
both complex genetic trait and environmental factors.1 There are two major forms 
of MS. Relapsing-remitting (RR) MS is the most frequent form (85%–90%) and 
affects women about twice as often as men. The majority of patients with RRMS 
later develop secondary progressive disease.2 About 10%–15% of patients present 
with insidious disease onset and steady progression, termed primary progressive 
MS. Although the factors responsible for the different disease courses are not com-
pletely understood, the relapsing forms of MS seem to be driven mainly by acute 
inflammation that is initiated by adaptive immune cells, while neurodegeneration 
and chronic microglia-sustained inflammation seems to play a more important role 
in the progressive forms of the disease.3
Treatment options for RRMS have broadened remarkably in recent years. 
 Glatiramer acetate, interferon (IFN)-β preparations, mitoxantrone, natalizumab, 
 f ingolimod, alemtuzumab, dimethyl fumarate, and  teriflunomide are drugs 
approved to treat RRMS in several countries and have different efficacy and 
safety profiles. While glatiramer acetate and IFN-β preparations have been used 
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to treat MS for more than 20 years and have overall 
good safety profiles, the more recently approved treat-
ments are more effective but also come with more safety 
complications.
Natalizumab, a monoclonal antibody against the 
α4 subunit (CD49d) of α4 integrins (α4β1 and α4β7), is 
one of these new treatments, and is very effective but has 
a complicated safety profile. α4β1 integrin is expressed by 
all leukocytes except neutrophils and serves as an adhe-
sion molecule  mediating attachment to endothelial cells. 
Natalizumab prevents transmigration of leukocytes across 
the blood-brain barrier and the vascular endothelium of 
the gut by blocking α4β1 integrin/vascular cell adhesion 
molecule-1 and mucosal vascular addressin cell adhesion 
molecule-1 interaction.4–8
Natalizumab was approved by the US Food and 
Drug Administration (FDA) in 2004 for RRMS based 
on its high efficacy and good safety profile even before 
completion of two placebo-controlled, multicenter Phase 
III clinical trials, ie, AFFIRM (Natalizumab Safety and 
Efficacy in RRMS) and SENTINEL (Safety and Efficacy 
of Natalizumab in  Combination with Interferon Beta-1a 
in Patients with RRMS).9,10 Only a few months after 
approval, a completely unexpected severe complication 
of natalizumab, ie, three cases of progressive multifocal 
leukoencephalopathy (PML), were identified in patients 
with MS and Crohn’s disease.11–13 The manufacturers vol-
untarily suspended natalizumab in 2005 pending a safety 
review. After the review, it was considered that the esti-
mated risk of PML was acceptable given the outstanding 
demonstrable therapeutic benefits of natalizumab, and the 
drug was reintroduced in the market in 2006 and approved 
by the FDA and European Medicines Agency for highly 
active RRMS, although with a pharmacovigilance plan to 
minimize the risk of PML. This plan involved a prescrib-
ing program developed by the FDA known as TOUCH 
(Tysabri Outreach  Unified Commitment to Health), which 
aimed to ensure that only prescribers and patients enrolled 
in TOUCH could prescribe or receive Tysabri. Eight years 
after licensing of natalizumab, considerable progress has 
been made in identification of risk factors for PML and 
approaches to risk minimization, and long-term studies to 
define better when to start or stop treatment and to optimize 
treatment strategies after cessation of natalizumab are 
 ongoing. However, the PML complication still jeopardizes 
one of the most valuable treatments available for MS. Here 
we review the long-term efficacy and safety of natalizumab 
in RRMS and the impact on quality of life.
Efficacy of natalizumab  
and impact on quality of life
Clinical trials
AFFIRM9 and SENTINEL10 are two large, randomized, dou-
ble-blind, placebo-controlled, multicenter Phase III  clinical 
trials that provided the initial data regarding the short-term 
efficacy and safety of natalizumab in patients with RRMS. 
AFFIRM compared the efficacy of natalizumab monotherapy 
(300 mg intravenously every 4 weeks) with placebo, while 
SENTINEL compared the efficacy of natalizumab when 
added to IFN-β1a with that of IFN-β1a  monotherapy. 
GLANCE (Glatiramer Acetate and  Natalizumab Combina-
tion  Evaluation) is also a published randomized, 24-week, 
 double-blind, placebo-controlled Phase II clinical trial that 
evaluated the efficacy, safety, and tolerability of natalizumab 
when added to glatiramer acetate in patients with RRMS.14 
The short-term efficacy and impact on quality of life of natali-
zumab in these clinical trials have been extensively reviewed 
previously,15,16 so are not covered in this review.
Clinical practice and real-life settings
The efficacy of natalizumab and its impact on quality of 
life have also been studied in different clinical practice and 
real-life settings. Natalizumab was approved as a second-
line treatment for patients in whom first-line treatments 
have failed and for patients with rapidly evolving MS. 
 Consequently, patients treated with natalizumab in clinical 
practice had in general more severe disease than patients 
in clinical trials, and the majority had received disease-
 modifying treatments. For this reason, it was assumed that the 
efficacy of natalizumab in clinical trials might differ from the 
experience in clinical practice. Several studies have examined 
the clinical efficacy of natalizumab in open-label cohorts 
and shown that these patient populations also benefit from 
treatment with natalizumab.17–21 The effect of natalizumab on 
Expanded Disability Status Scale (EDSS) scores was evalu-
ated in a retrospective study of patients treated for 44 weeks. 
In this study, treatment with natalizumab improved EDSS 
scores mainly in patients who had relapse-mediated worsen-
ing of EDSS.22 In addition, other studies also demonstrated 
an effect of treatment, with natalizumab improving visual 
acuity,23 visual evoked potential sum scores,24 and cognitive 
performance.25–27 In a small, prospective, magnetic resonance 
imaging (MRI) study,28 it was found that treatment with 
natalizumab over 2 years reduced cortical lesions and cortical 
atrophy when compared with untreated patients and patients 
treated with first-line therapies. This observation suggests 
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that natalizumab might, by reducing inflammation, generate 
a more favorable environment for remyelination. Supporting 
a role for natalizumab in reducing axonal damage, it was 
observed in a longitudinal cerebrospinal fluid study of 92 MS 
patients treated with natalizumab that neurofilament light 
chain, a marker of neurodegeneration, decreased to the levels 
found in normal donors.29
The first evaluation of the early effects of natalizumab 
on Patient-Reported Outcomes in a clinical setting was 
performed in MS patients (n=451) enrolled in the TOUCH 
prescribing program and who received their third  natalizumab 
infusion. This study demonstrated that natalizumab sig-
nificantly improved overall quality of life from baseline to 
3 months of follow-up in 46% of patients and maintained 
quality of life in 51%.30 Despite the short treatment dura-
tion, there was a significant improvement in disease level 
and functional status scores. Thirty percent of patients 
reported an improved functional status and 67% reported 
a stable functional status. Eighty percent of patients also 
reported an improvement in one or more physical items of 
the 29-item Multiple Sclerosis Impact Scale, in which the 
ability to perform physically demanding tasks was the item 
for which the highest improvement was reported. In addi-
tion, 75% of patients reported improvement in one or more 
psychological items, particularly for feeling well.30 In 2012, 
the first large, real-life, 12-month longitudinal study assessing 
the impact of natalizumab on Patient-Reported Outcomes 
was reported in 333 MS patients.31 After 12 months of 
treatment with natalizumab, 69%–88% of patients reported 
a positive outcome, either improvement or no decline, in 
all Patient-Reported Outcomes measures assessed. The 
improvements were observed as early as after 3 months of 
treatment and were sustained over a 12-month period. The 
improvements were observed with physical and psychologi-
cal measures, and significantly reduced the impact of MS on 
cognitive functioning and fatigue.31
A Swedish survey of natalizumab-treated patients that 
investigated the monetary value of treatment with natalizumab 
in terms of the ability to work showed that, after 50 weeks 
of treatment with natalizumab, MS patients increased their 
productivity by 3.3 hours per week on average (P,0.01).32 
Overall, 22% of patients increased their work capacity, 6% 
decreased their work capacity, and 72% were unchanged. 
A shorter duration of disease, younger age at the start of 
treatment, and being employed rather than self-employed were 
significantly associated with a greater productivity gain.32
The TYNERGY (Effects of Tysabri over 12 months on 
MS related fatigue in patients with RRMS) study that aimed 
to further evaluate the effects of treatment with natalizumab 
on MS-related fatigue has recently been reported.33 In this 
one-armed clinical trial, 195 MS patients were treated with 
natalizumab in a real-life setting for 12 months, and the 
effect of treatment on fatigue was evaluated using a validated 
questionnaire, ie, The Fatigue Scale for Motor and Cognitive 
Functions. All measured variables, ie, fatigue score, quality of 
life, sleepiness, depression, cognition, and disability progres-
sion, were improved from baseline to 12 months, as well as 
walking speed measured by the 6-minute walk test.33
Long-term follow-up
There are two large, ongoing observational studies of note 
for which some results are partially available. These studies 
are STRATA (Safety of Tysabri Re-dosing and Treatment) 
and TOP (Tysabri Observational Program).
STRATA is a long-term (up to 10 years), open-label, 
multinational, follow-up study of natalizumab monotherapy 
(300 mg intravenously every 4 weeks) in patients with RRMS 
who completed the AFFIRM, SENTINEL, and GLANCE 
trials and their open-label extensions, and is evaluating the 
long-term safety and efficacy of natalizumab. In March 
2013, after 4,135 patient-years of natalizumab exposure in 
STRATA (median of 64 natalizumab infusions), the annual-
ized relapse rate remained low at 0.15 relapses per patient 
per year. Mean EDSS scores increased in the time between 
completing the feeder studies and enrollment in STRATA. 
Mean EDSS scores for patients who originally received 
natalizumab or placebo, respectively, were 2.9 and 3.1 at 
STRATA baseline, 2.7 and 3.1 at week 48, 2.7 and 3.2 at week 
96, 2.8 and 3.2 at week 144, 2.9 and 3.2 at week 192, 2.8 
and 3.2 at week 240, and 2.9 and 3.2 at week 288.34 Overall, 
patients on natalizumab generally experienced stable EDSS 
scores and a low annualized relapse rate over time. Patients 
initially randomized to 2 years of treatment with natalizumab 
in the Phase III clinical trials retained their lower EDSS 
scores compared with those initially randomized to placebo. 
This suggests important advantages of early treatment with 
natalizumab.
TOP is a 10-year prospective, multinational, open-
label, post-marketing, observational study of the long-term 
clinical safety and efficacy of natalizumab in the Euro-
pean,  Australian, and Canadian settings. Patients must 
have active RRMS and be natalizumab-naïve (#3 doses 
prior to enrollment), but may have received other disease-
modifying therapies prior to natalizumab. A preliminary 
report on the TOP study was presented in June 2011. At 
that time, 3,484 patients from 15 countries were enrolled. 
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Overall, the mean EDSS score was 3.5 at baseline and 
3.4 after 3 years. The overall annualized relapse rate was 
significantly decreased from baseline (1.98) to post-baseline 
(0.28, P,0.0001). Annualized relapse rates at baseline were 
similar (1.91–2.03) regardless of the patient’s previous 
therapy, but after 3 years of treatment with natalizumab, the 
annualized relapse rates differed  significantly according to 
pre-enrollment therapy (P,0.0001), ie, therapy-naïve (0.16), 
prior IFN (0.20), prior glatiramer acetate (0.23), prior IFN/
glatiramer acetate or glatiramer acetate/IFN (0.25), and prior 
immunosuppression (0.34).35
After this general update, two subsequent updates have 
been presented. One update reported TOP results obtained 
in the UK until June 2012.36 At that time, 117 patients 
were enrolled in the UK and received a median of 15 
(range 1–27) natalizumab infusions. The median number 
of relapses in the year prior to treatment with natalizumab 
was 2.0, 24.8% of the patients had one relapse, and 75.2% 
had more than one relapse. The overall annualized relapse 
rate decreased from 2.26 at baseline to 0.38 on treatment 
(P,0.0001). The annualized relapse rate decreased sig-
nificantly from baseline regardless of baseline treatment 
history and relapse history. In treatment-naïve patients, 
the relapse rate was 2.54 at baseline versus 0.48 on treat-
ment (P,0.0001). In patients previously treated with one 
disease-modifying therapy, the relapse rate was 2.14 at 
baseline versus 0.36 on treatment (P,0.0001). In patients 
with more than one prior disease-modifying treatment, the 
relapse rate was 2.00 at baseline versus 0.26 on treatment 
(P=0.0003). Regarding history of relapse, in patients with 
one relapse in the prior year, the relapse rate was 1.00 
at baseline versus 0.27 on treatment (P,0.001), and in 
patients with more than one relapse in the prior year, the 
relapse rate was 2.67 at baseline versus 0.43 on treatment 
(P,0.0001). EDSS scores were stable, with a mean of 
4.2 at baseline, 4.0 at month 6, 4.4 at year 1, and 4.3 at year 
2. This interim analysis of TOP results in the UK indicated 
that treatment with natalizumab improves the annualized 
relapse rate, regardless of baseline treatment or relapse 
history, and stabilizes EDSS scores.36
A second observational study reported TOP results 
obtained in Germany until February 2012.37 In this study, 
the annualized relapse rate in the year prior to treatment with 
natalizumab was 2.2, the EDSS was 3.5, and the Demtect 
cognitive function score at baseline was 14.9. After  treatment 
with natalizumab, the relapse rate decreased to 0.14, the 
EDSS stabilized at 3.5, and the Demtect score increased to 
16.0. This interim study confirms the sustained efficacy of 
natalizumab in reducing clinical disease activity.
Safety of natalizumab  
and impact on quality of life
Progressive multifocal  
leukoencephalopathy
PML is a demyelinating disorder of the CNS caused by John 
Cunningham virus (JCV) infection.38,39 JCV is a ubiquitous 
virus, which infects 60%–80% of the population  worldwide 
without clinical consequences, but can cause PML under 
 circumstances of immunocompromise and especially 
impaired CD4+ T cell function, such as in late-stage human 
immunodeficiency virus infection, hematological malig-
nancies, and organ transplantation, and also in clinically 
inconspicuous idiopathic CD4+ lymphopenia.38,40,41 PML 
has recently emerged as a serious adverse event during 
monoclonal antibody treatment of autoimmune diseases, 
especially in MS patients treated with natalizumab. The first 
two cases of PML in natalizumab-treated patients developed 
during premarketing studies, with one case occurring in the 
SENTINEL trial after 28 doses of natalizumab and the other 
in the open-label extension of SENTINEL after 37 doses of 
natalizumab.11,12 One patient died from PML and the other 
patient with PML progressed rapidly. These cases were fol-
lowed by a case of PML after eight infusions of natalizumab 
in a patient with Crohn’s disease.13
As mentioned above, after these PML cases, the 
manufacturer voluntarily suspended natalizumab in 2005 pend-
ing a safety review. In March 2006, an extensive safety study of 
3,116 patients with MS, Crohn’s disease, or  rheumatoid arthri-
tis who received treatment with  natalizumab were assessed for 
PML.42 Of these, 44 were referred to the expert panel because 
of clinical findings of possible PML, abnormalities on MRI, 
or a high plasma load of JCV. No patient had detectable JCV 
DNA in cerebrospinal fluid. PML was ruled out in 43 of the 
44 patients, but could not be ruled out in one patient because 
cerebrospinal fluid and follow-up MRI were not available.42 
No new PML cases were identified in this study, suggesting 
a risk of PML of roughly one in 1,000 patients treated with 
natalizumab for a mean of 17.9 months.
Based on this study, it was considered that the esti-
mated risk of PML was acceptable given the demonstrably 
 outstanding therapeutic benefits of natalizumab, and the 
drug was reintroduced in the market in June 2006 and 
approved by the FDA and European Medicines Agency 
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for highly active RRMS. Since then, the number of cases 
of PML has continued to increase. As of February 2012, 
212 confirmed PML cases among 99,571 patients treated 
with natalizumab were reported, giving an incidence of 
2.1 cases per 1,000 patients.43 Twenty-two percent of these 
PML patients died and 40% of the evaluable survivors had 
severe disability. As of March 2013, the number of patients 
with confirmed PML was 343 among more than 112,000 
treated patients, giving a risk of PML associated with 
natalizumab of 2.96 cases per 1,000 patients.44 The mean 
duration of treatment in these patients was 39 months. The 
most recent media release, in December 2013,45 indicates an 
overall incidence of PML in natalizumab-treated patients of 
3.41 cases per 1,000 patients.
In general, the outcome of natalizumab-associated PML is 
better than in PML associated with human immunodeficiency 
virus. Two case series studies demonstrated that around 70% 
of natalizumab-associated PML cases survived and that 
 survival is correlated with younger age, lower EDSS prior to 
diagnosis, lower JCV load at diagnosis, and more localized 
brain involvement on MRI at the time of diagnosis.46,47 The 
most recent media release from December 2013 indicates 
that 77% of the PML patients are alive, with varying levels 
of disability. However, despite this better outcome of PML 
in MS patients, cessation of natalizumab therapy in these 
patients could have serious negative consequences. Unlike 
general immunosuppression, natalizumab therapy selectively 
compromises immune surveillance only in the CNS and gut, 
and only during treatment. Cessation of natalizumab therapy 
in MS patients who develop PML re-establishes immune 
 surveillance in the CNS and leads to an inflammatory 
response known as PML immune reconstitution inflammatory 
syndrome, which allows efficient destruction of JCV-infected 
cells and eradication of the virus,48,49 but can also lead to rapid 
deterioration of the patient’s clinical state and death in about 
30%–50% of cases.49 The cellular and molecular pathogenesis 
of PML immune reconstitution inflammatory syndrome is not 
completely understood, but histological analysis of biopsy 
samples demonstrated that both CD850 and CD451 inflamma-
tion dominated the T cell infiltrate.
During 8 years of use of natalizumab as a treatment for 
MS, considerable progress has been made in identification 
of risk factors for PML and approaches to risk minimization. 
Positive status with respect to anti-JCV antibodies, prior use 
of immunosuppressants, and increased duration of treatment 
with natalizumab (more than 2 years) are the main PML 
risk factors identified.43 The estimated incidence of PML 
in patients with all three risk factors was 11.1 cases per 
1,000 patients, compared with an estimated incidence of 
0.09 cases per 1,000 in the group of patients negative for JCV 
antibodies.43 Based on this risk stratification, treatment rec-
ommendations have been proposed52 that include testing for 
JCV antibodies prior to starting treatment with natalizumab 
and every 6 months thereafter. As of December 2013, results 
of the anti-JCV antibody assay have been reliable in stratify-
ing PML risk; 99% of PML patients with available pre-PML 
samples tested positive for anti-JCV antibodies.
The incidence of PML in natalizumab-treated patients is 
higher in Europe than in the USA, and the treatment duration 
beyond which the risk for PML increases is also longer in the 
USA. Although the reason for this difference is unknown, 
it has been proposed that it might be related to body mass 
index. It has been hypothesized that a low body mass might 
translate into higher concentrations of natalizumab in plasma, 
higher or more complete VLA-4 saturation rates in immune 
cells, and a consequently decreased immunosurveillance 
of the CNS and a higher incidence of PML.53 Reducing the 
natalizumab dose or increasing the interval between infusions 
may reduce this risk.
Regarding biomarkers for risk of PML, it was recently 
reported that the percentage of L-selectin- expressing CD4+ 
T cells was significantly lower in patients on long-term 
treatment with natalizumab (40.2%) when compared with 
patients not receiving natalizumab (47.2%, P=0.016) and 
healthy controls (61.0%, P,0.0001).54 This unusually low 
percentage correlated with the risk of developing PML in 
the patient group with available pre-PML samples when 
compared with natalizumab-treated patients without PML 
(P#0.0001). These results suggest that a low percentage 
of L-selectin-expressing CD4+ T cells might be useful as a 
biomarker for individual PML risk.
It has also been suggested that natalizumab might reduce 
T cell responses against JCV in peripheral blood, facilitat-
ing reactivation of JCV. It has been reported that subclinical 
reactivation of JCV occurs frequently in natalizumab-treated 
patients and that viral shedding is associated with a transient 
drop in JCV-specific cellular immune responses,55 suggesting 
that monitoring JCV-specific T cell responses might be an 
interesting biomarker for risk of PML. However, neither the 
reduced T cell response nor viral reactivation in peripheral 
blood during treatment with natalizumab has been reproduced 
in other studies.56,57
Treatment with natalizumab not only compromises 
immune surveillance of the CNS, but also mobilizes 
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 lymphoid hematopoietic precursor cells from the bone 
 marrow58–61 and induces significant sustained phenotypic 
changes in the immune cell composition of peripheral 
blood, such as an increase in T cells, natural killer cells, 
and  especially B cells, and a decrease in monocytes,61–64 
suggesting that there is no desensitization effect after 
prolonged exposure to natalizumab.65 Mobilization of 
lymphoid precursors and B cells might contribute to 
development of PML, given that this might result in a 
significant increase in cells that are in principle able to 
produce and spread progeny virus.  Monitoring circulating 
JCV-infected hematopoietic cells and B cells might be an 
interesting biomarker for risk of PML and deserves further 
investigation.
Other issues with natalizumab
Short-term side effects
Natalizumab is generally well tolerated, and few short-term 
side effects were reported in the Phase III AFFIRM and 
SENTINEL clinical trials.9,10 The more common reported 
side effects were nonserious, and included fatigue, anxi-
ety, pharyngitis, sinus congestion, peripheral edema, and 
 allergic reactions. Allergic reactions are often associated 
with the presence of antibodies against natalizumab. Data 
from the Phase III clinical trials indicated a higher per-
centage of allergic reactions in treated individuals than 
in those on placebo, and around 10% of treated patients 
developed anti-natalizumab antibodies.9,10 Persistently high 
anti-natalizumab antibody titers are associated with a lack 
of drug efficacy, a reduction in the monoclonal antibody 
concentration in serum, and infusion-related hypersensitiv-
ity reactions.66,67 The short-term side effects of natalizumab 
in these clinical trials have been previously reviewed in 
detail.15,16
Natalizumab, like other T cell immunomodulatory treat-
ments, has been associated with liver injury. Although this is 
not a common side effect, some cases have been reported of 
MS patients who developed serious liver injury after their first 
natalizumab infusion.68,69 Patients developed increased serum 
aminotransferases and hyperbilirubinemia and sometimes 
signs of autoimmune hepatitis, such as autoantibodies and liver 
inflammation. These adverse events normally appeared after the 
first natalizumab infusion and remitted after discontinuation 
of treatment. Although the mechanism by which natalizumab 
might induce liver damage is unknown, it is recommended to 
monitor for signs of autoimmune hepatitis or atypical viral 
infections before and during treatment with natalizumab.
Long-term side effects
Long-term impaired immunosurveillance in MS patients 
treated with natalizumab has been associated with sev-
eral opportunistic infections other than JCV, although a 
higher risk has not been proven. Human herpesvirus-6 
(HHV-6) is a pleiotropic β-herpesvirus that infects cells 
in the CNS. HHV-6 is commonly reactivated in situations 
of immunosuppression and has been associated with MS.70 
Several lines of evidence, including an increase in the level 
of HHV-6-specific antibodies in serum and an increase in 
HHV-6 DNA in the cerebrospinal fluid of natalizumab-
treated MS patients, suggest that HHV-6 might reactivate 
on treatment with natalizumab.71,72 Herpes simplex and vari-
cella zoster CNS infections have recently been reported in 
20 natalizumab-treated MS patients.73,74 Finally, a single case 
of ocular  toxoplasmosis has been reported after 11 months 
of treatment with natalizumab.75 Toxoplasma gondii infects 
30% of the population without causing symptoms, but in 
immunocompromised individuals can reactivate and lead 
to organ damage.76
The relationship between long-term treatment with 
natalizumab and a higher susceptibility to developing 
malignancy is still under debate. Several cases of malig-
nant melanoma while on treatment with natalizumab have 
been reported.77–80 However, the prevalence of melanoma 
was not different when comparing natalizumab-treated 
and untreated MS patients.78 Single cases of primary CNS 
lymphoma and peripheral T cell lymphoma have been 
reported in  natalizumab-treated MS patients,81,82 although a 
direct cause-effect relationship has not been demonstrated. 
Other hematologic changes, such as hypereosinophilia, 
immune-mediated acute hemolytic  anemia, and immune 
thrombocytopenic purpura, have occasionally been reported 
in natalizumab-treated MS patients.16
Impact on quality of life
Not only the risk of PML, but also other adverse events, 
such as hypersensitivity reactions, recurrent infections, or 
malignancies, or other conditions, such as pregnancy, might 
render it advisable to discontinue natalizumab.83 Given that 
natalizumab is a treatment with high benefits along with 
very severe risks, experts have advocated an informed re-
consent for patients after 2 years of treatment with natali-
zumab. Although a good understanding of the benefits and 
risks is important regarding the decision whether to continue 
or stop treatment, the perception of risk differs between 
patients and neurologists. In a study published in 2010, 
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when the estimated risk for natalizumab-induced PML in 
MS patients treated for more than 2 years was about one 
in 1,000, patients perceived MS as a malignant disease, 
so were willing to accept a considerably higher PML risk 
than neurologists.84 Identification in recent years of JCV 
seropositivity, duration of treatment with natalizumab, 
and prior immunosuppression as risk factors, has modi-
fied this acceptance of risk. Although the large majority 
of JCV-seropositive patients are still willing to continue 
treatment, seropositive patients have elevated anxiety levels, 
are less secure about their decision to continue treatment, 
feel less safe, and are more afraid of PML.85
One important complication of cessation of natalizumab 
with crucial consequences for patients is that it is presently 
not known which treatment strategy is the more appropri-
ate to follow after stopping treatment with natalizumab.83 
It is known that disease activity returns to pretreatment 
levels or even above within 4–7 months from the last 
natalizumab infusion, so patients stopping natalizumab 
are at considerable risk of rebound relapse/inflammatory 
activity and worsening MS-related disability.86 Several 
strategies have been used to avoid disease activity after 
discontinuation of natalizumab. One of these strategies, 
which unfortunately has not been very effective, was 
use of methylprednisolone as a bridge before switching 
to glatiramer acetate or IFN-β. Better results have been 
obtained in some case series using fingolimod as subse-
quent therapy, although long-term data on the efficacy and 
safety of fingolimod after cessation of natalizumab are 
still missing. Other therapies available, such as fumarate, 
might represent a good alternative to optimize escalation 
treatment for patients who stop natalizumab, but further 
long-term studies are needed.
The clinical experience with natalizumab has provided 
important lessons. While the drug continues to be perceived 
as highly effective and well tolerated overall, the risk of PML 
remains an important safety concern, that is not solved at 
present despite risk stratification algorithms. Accordingly, last 
December, the FDA approved a label update, announcing that 
natalizumab is no longer generally recommended for those 
who have responded inadequately to or are unable to tolerate 
alternative MS therapy.87 Further important  questions that 
merit more detailed investigation are whether certain mark-
ers can allow us to identify patients who will show severe 
rebound disease activity after cessation of natalizumab, how 
to switch over from natalizumab to other drugs, and over 
what periods of time.
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